CTAS vs INBX · P/E 51, rev $11.26B vs rev $1.3M
Cintas Corporation (CTAS) versus Inhibrx Biosciences, Inc. (INBX) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on US.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported INBX revenue for 2025-12-31 was $1.3M. Net income was -$140.1M. Revenue was up 550.0% from 2024-12-31 to 2025-12-31. INBX currently screens at market cap $1.28B.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. INBX currently screens at market cap $1.28B.
Not investment advice. Open the CTAS and INBX stock pages for the full models.
Not investment advice.